These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 24321374)
1. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial. Flanigan KM; Voit T; Rosales XQ; Servais L; Kraus JE; Wardell C; Morgan A; Dorricott S; Nakielny J; Quarcoo N; Liefaard L; Drury T; Campion G; Wright P Neuromuscul Disord; 2014 Jan; 24(1):16-24. PubMed ID: 24321374 [TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study. Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424 [TBL] [Abstract][Full Text] [Related]
3. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy. Goemans N; Mercuri E; Belousova E; Komaki H; Dubrovsky A; McDonald CM; Kraus JE; Lourbakos A; Lin Z; Campion G; Wang SX; Campbell C; Neuromuscul Disord; 2018 Jan; 28(1):4-15. PubMed ID: 29203355 [TBL] [Abstract][Full Text] [Related]
4. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study. Hilhorst N; Spanoudi-Kitrimi I; Goemans N; Morren MA Eur J Pediatr; 2019 Feb; 178(2):253-258. PubMed ID: 30448867 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738 [TBL] [Abstract][Full Text] [Related]
6. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids. Goemans N; Tulinius M; Kroksmark AK; Wilson R; van den Hauwe M; Campion G Neuromuscul Disord; 2017 Mar; 27(3):203-213. PubMed ID: 28169120 [TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177 [TBL] [Abstract][Full Text] [Related]
8. Exon skipping therapy for Duchenne muscular dystrophy. Kole R; Krieg AM Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936 [TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP; JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377 [TBL] [Abstract][Full Text] [Related]
10. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124 [TBL] [Abstract][Full Text] [Related]
11. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Hammond SM; Wood MJ Curr Opin Mol Ther; 2010 Aug; 12(4):478-86. PubMed ID: 20677099 [TBL] [Abstract][Full Text] [Related]
12. Viltolarsen for the treatment of Duchenne muscular dystrophy. Roshmi RR; Yokota T Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560 [TBL] [Abstract][Full Text] [Related]